{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:40:03Z","timestamp":1792190403330,"version":"4.4.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Autologous cellular immunotherapies, which rely on cytotoxic T lymphocytes (CTLs), are increasingly applied in different B-cell malignancies. The general assumption is that CTLs exert their cytolytic function through granzymes that induce apoptosis in the target cell. However, the killing mechanism of immunotherapeutic CTLs is not clearly elucidated. Using T-cell redirecting bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T-cells we assessed which cell death pathways were activated in B cell line models as well as in primary material from CLL patients. We demonstrate that for cytotoxic T-cell killing of malignant B-cells by any of the treatment strategies, caspase activity was not essential. We could also exclude a role for TNF or TRAIL-mediated pathways. Using electron microscopy, CAR T-cell and BsAb-mediated cell death showed a mixed apoptotic\/necroptotic phenotype. This was corroborated by knockout and chemical inhibition of the essential necroptosis proteins RIPK1, RIPK3, and MLKL. Necroptotic death of target cells correlated with the release of HMGB1 in the supernatant as well as various immunomodulatory molecules from the T-cells. Besides known immune activators IFN-y, IL-17 and IL-6, also anti-inflammatory IL-10 and IL1-RA were released. Moreover, the quantity of these immunomodulators was differentially affected after application of apoptosis versus necroptosis inhibitors. Together, these data demonstrate that (CAR) T-cell-mediated killing of lymphoma cells has a necroptotic arm which is correlated with modulation of the wider immune response. They imply that manipulation of the apoptotic versus necroptotic balance in immunotherapy could affect engagement of the autologous immune response.<\/jats:p>","DOI":"10.1038\/s41419-026-08993-7","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:06:16Z","timestamp":1782389176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Necroptotic cell death and immunomodulator release induced by T-cell engaging anti-lymphoma therapies"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3850-9913","authenticated-orcid":false,"given":"Demi","family":"Both","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Saura-Esteller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-2482","authenticated-orcid":false,"given":"Anne","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Rietveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4575-1257","authenticated-orcid":false,"given":"Ingrid","family":"Derks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris","family":"Mes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Willem","family":"Duitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Grootemaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"van der Wel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3190-1891","authenticated-orcid":false,"given":"Arnon","family":"Kater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1410-7285","authenticated-orcid":false,"given":"Marco","family":"Haselager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0561-6640","authenticated-orcid":false,"given":"Eric","family":"Eldering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"8993_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","volume":"58","author":"P Bose","year":"2017","unstructured":"Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017;58:1\u201317.","journal-title":"Leuk Lymphoma"},{"key":"8993_CR2","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1056\/NEJMc1402716","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Cheng S, Lu P, Setty M, Perez AR, Guo A, et al. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med. 2014;370:2352\u20134.","journal-title":"N Engl J Med"},{"key":"8993_CR3","doi-asserted-by":"crossref","unstructured":"van Bruggen JAC, Martens AWJ, Tonino SH, Kater AP. Overcoming the hurdles of autologous T-cell-based therapies in B-cell non-hodgkin lymphoma. Cancers. 2020;12:3837.","DOI":"10.3390\/cancers12123837"},{"key":"8993_CR4","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.3324\/haematol.2015.124560","volume":"100","author":"R Thijssen","year":"2015","unstructured":"Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MH, et al. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica. 2015;100:e302\u20136.","journal-title":"Haematologica"},{"key":"8993_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood-2016-12-759621","volume":"130","author":"N Tsuyama","year":"2017","unstructured":"Tsuyama N, Sakata S, Baba S, Mishima Y, Nishimura N, Ueda K, et al. BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. Blood. 2017;130:489\u2013500.","journal-title":"Blood"},{"key":"8993_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1172\/JCI28281","volume":"117","author":"V Del Gaizo Moore","year":"2007","unstructured":"Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Investig. 2007;117:112\u201321.","journal-title":"J Clin Investig"},{"key":"8993_CR7","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1182\/blood.V91.9.3379","volume":"91","author":"S Kitada","year":"1998","unstructured":"Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood. 1998;91:3379\u201389.","journal-title":"Blood"},{"key":"8993_CR8","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1126\/science.3874430","volume":"228","author":"Y Tsujimoto","year":"1985","unstructured":"Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985;228:1440\u20133.","journal-title":"Science"},{"key":"8993_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1182\/blood.V98.3.787","volume":"98","author":"WK Hofmann","year":"2001","unstructured":"Hofmann WK, de Vos S, Tsukasaki K, Wachsman W, Pinkus GS, Said JW, et al. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood. 2001;98:787\u201394.","journal-title":"Blood"},{"key":"8993_CR10","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/ng.2652","volume":"45","author":"SI Berndt","year":"2013","unstructured":"Berndt SI, Skibola CF, Joseph V, Camp NJ, Nieters A, Wang Z, et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet. 2013;45:868\u201376.","journal-title":"Nat Genet"},{"key":"8993_CR11","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1182\/blood.V99.11.4094","volume":"99","author":"MS Shin","year":"2002","unstructured":"Shin MS, Kim HS, Kang CS, Park WS, Kim SY, Lee SN, et al. Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood. 2002;99:4094\u20139.","journal-title":"Blood"},{"key":"8993_CR12","doi-asserted-by":"crossref","unstructured":"Martens AWJ, Janssen SR, Derks IAM, Adams Iii HC, Izhak L, van Kampen R, et al. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells. J Immunother Cancer. 2020;8:e000218.","DOI":"10.1136\/jitc-2019-000218"},{"key":"8993_CR13","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nri911","volume":"2","author":"JA Trapani","year":"2002","unstructured":"Trapani JA, Smyth MJ. Functional significance of the perforin\/granzyme cell death pathway. Nat Rev Immunol. 2002;2:735\u201347.","journal-title":"Nat Rev Immunol"},{"key":"8993_CR14","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1126\/science.7518614","volume":"265","author":"D Kagi","year":"1994","unstructured":"Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 1994;265:528\u201330.","journal-title":"Science"},{"key":"8993_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/sj.cdd.4402244","volume":"15","author":"SP Cullen","year":"2008","unstructured":"Cullen SP, Martin SJ. Mechanisms of granule-dependent killing. Cell Death Differ. 2008;15:251\u201362.","journal-title":"Cell Death Differ"},{"key":"8993_CR16","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/cdd.2009.206","volume":"17","author":"SP Cullen","year":"2010","unstructured":"Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ. 2010;17:616\u201323.","journal-title":"Cell Death Differ"},{"key":"8993_CR17","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/0092-8674(94)90376-X","volume":"76","author":"JW Heusel","year":"1994","unstructured":"Heusel JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell. 1994;76:977\u201387.","journal-title":"Cell"},{"key":"8993_CR18","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.1074\/jbc.M410985200","volume":"280","author":"NJ Waterhouse","year":"2005","unstructured":"Waterhouse NJ, Sedelies KA, Browne KA, Wowk ME, Newbold A, Sutton VR, et al. A central role for Bid in granzyme B-induced apoptosis. J Biol Chem. 2005;280:4476\u201382.","journal-title":"J Biol Chem"},{"key":"8993_CR19","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/377446a0","volume":"377","author":"AJ Darmon","year":"1995","unstructured":"Darmon AJ, Nicholson DW, Bleackley RC. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature. 1995;377:446\u20138.","journal-title":"Nature"},{"key":"8993_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.0105-2896.2010.00908.x","volume":"235","author":"IS Afonina","year":"2010","unstructured":"Afonina IS, Cullen SP, Martin SJ. Cytotoxic and non-cytotoxic roles of the CTL\/NK protease granzyme B. Immunol Rev. 2010;235:105\u201316.","journal-title":"Immunol Rev"},{"key":"8993_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1365-2567.2011.03426.x","volume":"133","author":"D Hassin","year":"2011","unstructured":"Hassin D, Garber OG, Meiraz A, Schiffenbauer YS, Berke G. Cytotoxic T lymphocyte perforin and Fas ligand working in concert even when Fas ligand lytic action is still not detectable. Immunology. 2011;133:190\u20136.","journal-title":"Immunology"},{"key":"8993_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1600-065X.2011.01044.x","volume":"243","author":"EA Miao","year":"2011","unstructured":"Miao EA, Rajan JV, Aderem A. Caspase-1-induced pyroptotic cell death. Immunol Rev. 2011;243:206\u201314.","journal-title":"Immunol Rev"},{"key":"8993_CR23","doi-asserted-by":"crossref","unstructured":"Zhou Z, He H, Wang K, Shi X, Wang Y, Su Y, et al. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science. 2020;368:eaaz7548.","DOI":"10.1126\/science.aaz7548"},{"key":"8993_CR24","doi-asserted-by":"crossref","unstructured":"Snyder AG, Hubbard NW, Messmer MN, Kofman SB, Hagan CE, Orozco SL, et al. Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity. Sci Immunol. 2019;4:eaaw2004.","DOI":"10.1126\/sciimmunol.aaw2004"},{"key":"8993_CR25","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.molcel.2017.02.024","volume":"65","author":"CJ Kearney","year":"2017","unstructured":"Kearney CJ, Martin SJ. An inflammatory perspective on necroptosis. Mol Cell. 2017;65:965\u201373.","journal-title":"Mol Cell"},{"key":"8993_CR26","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1126\/science.aad0395","volume":"350","author":"N Yatim","year":"2015","unstructured":"Yatim N, Jusforgues-Saklani H, Orozco S, Schulz O, Barreira da Silva R, Reis e Sousa C, et al. RIPK1 and NF-kappaB signaling in dying cells determines cross-priming of CD8(+) T cells. Science. 2015;350:328\u201334.","journal-title":"Science"},{"key":"8993_CR27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.celrep.2016.03.037","volume":"15","author":"TL Aaes","year":"2016","unstructured":"Aaes TL, Kaczmarek A, Delvaeye T, De Craene B, De Koker S, Heyndrickx L, et al. Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep. 2016;15:274\u201387.","journal-title":"Cell Rep"},{"key":"8993_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-023-00450-w","volume":"12","author":"F Favaro","year":"2023","unstructured":"Favaro F, Both D, Derks IAM, Spaargaren M, Munoz-Pinedo C, Eldering E. Negligible role of TRAIL death receptors in cell death upon endoplasmic reticulum stress in B-cell malignancies. Oncogenesis. 2023;12:6.","journal-title":"Oncogenesis"},{"key":"8993_CR29","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.4049\/jimmunol.156.10.3678","volume":"156","author":"T Kataoka","year":"1996","unstructured":"Kataoka T, Shinohara N, Takayama H, Takaku K, Kondo S, Yonehara S, et al. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol. 1996;156:3678\u201386.","journal-title":"J Immunol"},{"key":"8993_CR30","doi-asserted-by":"crossref","unstructured":"Walsh RM, Ambrose J, Jack JL, Eades AE, Bye BA, Tannus Ruckert M, et al. Depletion of tumor-derived CXCL5 improves T cell infiltration and anti-PD-1 therapy response in an obese model of pancreatic cancer. J Immunother Cancer. 2025;13:e010057.","DOI":"10.1136\/jitc-2024-010057"},{"key":"8993_CR31","doi-asserted-by":"crossref","unstructured":"Alam MS, Otsuka S, Wong N, Abbasi A, Gaida MM, Fan Y, et al. TNF plays a crucial role in inflammation by signaling via T cell TNFR2. Proc Natl Acad Sci USA. 2021;118:e2109972118.","DOI":"10.1073\/pnas.2109972118"},{"key":"8993_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1152\/physrev.00013.2006","volume":"87","author":"G Kroemer","year":"2007","unstructured":"Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007;87:99\u2013163.","journal-title":"Physiol Rev"},{"key":"8993_CR33","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41586-019-1770-6","volume":"575","author":"M Fritsch","year":"2019","unstructured":"Fritsch M, Gunther SD, Schwarzer R, Albert MC, Schorn F, Werthenbach JP, et al. Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature. 2019;575:683\u20137.","journal-title":"Nature"},{"key":"8993_CR34","doi-asserted-by":"crossref","unstructured":"Han T, Ruan C, Lin H, Zhang Y, Li L, Sun YH, et al. RIPK1 S161 phosphorylation promotes further autophosphorylation and cecal necroptosis in TNF-treated mice. J Exp Med. 2025;222:e20250277.","DOI":"10.1084\/jem.20250277"},{"key":"8993_CR35","doi-asserted-by":"crossref","unstructured":"Koerner L, Li X, Silnov E, Laurien L, Pasparakis M. RIPK1 autophosphorylation at S161 mediates cell death and inflammation. J Exp Med. 2025;222:e20250277.","DOI":"10.1084\/jem.20250279"},{"key":"8993_CR36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nchembio711","volume":"1","author":"A Degterev","year":"2005","unstructured":"Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1:112\u20139.","journal-title":"Nat Chem Biol"},{"key":"8993_CR37","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.molcel.2014.10.021","volume":"56","author":"P Mandal","year":"2014","unstructured":"Mandal P, Berger SB, Pillay S, Moriwaki K, Huang C, Guo H, et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell. 2014;56:481\u201395.","journal-title":"Mol Cell"},{"key":"8993_CR38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.cell.2011.11.031","volume":"148","author":"L Sun","year":"2012","unstructured":"Sun L, Wang H, Wang Z, He S, Chen S, Liao D, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148:213\u201327.","journal-title":"Cell"},{"key":"8993_CR39","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41586-019-1548-x","volume":"574","author":"K Newton","year":"2019","unstructured":"Newton K, Wickliffe KE, Dugger DL, Maltzman A, Roose-Girma M, Dohse M, et al. Cleavage of RIPK1 by caspase-8 is crucial for limiting apoptosis and necroptosis. Nature. 2019;574:428\u201331.","journal-title":"Nature"},{"key":"8993_CR40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.immuni.2013.02.003","volume":"38","author":"A Kaczmarek","year":"2013","unstructured":"Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity. 2013;38:209\u201323.","journal-title":"Immunity"},{"key":"8993_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59818-8","volume":"16","author":"T Kimman","year":"2025","unstructured":"Kimman T, Cuenca M, Tieland RG, Rockx-Brouwer D, Janssen J, Motais B, et al. Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation. Nat Commun. 2025;16:4638.","journal-title":"Nat Commun"},{"key":"8993_CR42","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1002\/eji.1830271250","volume":"27","author":"JP Medema","year":"1997","unstructured":"Medema JP, Toes RE, Scaffidi C, Zheng TS, Flavell RA, Melief CJ, et al. Cleavage of FLICE (caspase-8) by granzyme B during cytotoxic T lymphocyte-induced apoptosis. Eur J Immunol. 1997;27:3492\u20138.","journal-title":"Eur J Immunol"},{"key":"8993_CR43","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/cdd.2017.65","volume":"24","author":"S Grootjans","year":"2017","unstructured":"Grootjans S, Vanden Berghe T, Vandenabeele P. Initiation and execution mechanisms of necroptosis: an overview. Cell Death Differ. 2017;24:1184\u201395.","journal-title":"Cell Death Differ"},{"key":"8993_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1480027","volume":"16","author":"K Yao","year":"2025","unstructured":"Yao K, Shi Z, Zhao F, Tan C, Zhang Y, Fan H, et al. RIPK1 in necroptosis and recent progress in related pharmaceutics. Front Immunol. 2025;16:1480027.","journal-title":"Front Immunol"},{"key":"8993_CR45","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.2019002121","volume":"135","author":"O Dufva","year":"2020","unstructured":"Dufva O, Koski J, Maliniemi P, Ianevski A, Klievink J, Leitner J, et al. Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood. 2020;135:597\u2013609.","journal-title":"Blood"},{"key":"8993_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100655","volume":"3","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Kong X, Ligtenberg MA, van Hal-van Veen SE, Visser NL, de Bruijn B, et al. RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells. Cell Rep Med. 2022;3:100655.","journal-title":"Cell Rep Med"},{"key":"8993_CR47","doi-asserted-by":"crossref","unstructured":"Chun N, Ang RL, Chan M, Fairchild RL, Baldwin WM, 3rd, et al. T cell-derived tumor necrosis factor induces cytotoxicity by activating RIPK1-dependent target cell death. JCI Insight. 2021;6:e148643.","DOI":"10.1172\/jci.insight.148643"},{"key":"8993_CR48","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s43018-023-00570-7","volume":"4","author":"M Boulch","year":"2023","unstructured":"Boulch M, Cazaux M, Cuffel A, Guerin MV, Garcia Z, Alonso R, et al. Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-gamma is a major determinant of CD4(+) CAR T-cell antitumor activity. Nat Cancer. 2023;4:968\u201383.","journal-title":"Nat Cancer"},{"key":"8993_CR49","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1365-2567.2009.03241.x","volume":"129","author":"K Padhan","year":"2010","unstructured":"Padhan K, Varma R. Immunological synapse: a multi-protein signalling cellular apparatus for controlling gene expression. Immunology. 2010;129:322\u20138.","journal-title":"Immunology"},{"key":"8993_CR50","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.4049\/jimmunol.177.8.5668","volume":"177","author":"A Hombach","year":"2006","unstructured":"Hombach A, Kohler H, Rappl G, Abken H. Human CD4+ T cells lyse target cells via granzyme\/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor. J Immunol. 2006;177:5668\u201375.","journal-title":"J Immunol"},{"key":"8993_CR51","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nchembio.83","volume":"4","author":"A Degterev","year":"2008","unstructured":"Degterev A, Hitomi J, Germscheid M, Ch\u2019en IL, Korkina O, Teng X, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008;4:313\u201321.","journal-title":"Nat Chem Biol"},{"key":"8993_CR52","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.cell.2009.05.021","volume":"137","author":"S He","year":"2009","unstructured":"He S, Wang L, Miao L, Wang T, Du F, Zhao L, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell. 2009;137:1100\u201311.","journal-title":"Cell"},{"key":"8993_CR53","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.cell.2014.04.018","volume":"157","author":"CP Dillon","year":"2014","unstructured":"Dillon CP, Weinlich R, Rodriguez DA, Cripps JG, Quarato G, Gurung P, et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3. Cell. 2014;157:1189\u2013202.","journal-title":"Cell"},{"key":"8993_CR54","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.celrep.2013.10.034","volume":"5","author":"SW Tait","year":"2013","unstructured":"Tait SW, Oberst A, Quarato G, Milasta S, Haller M, Wang R, et al. Widespread mitochondrial depletion via mitophagy does not compromise necroptosis. Cell Rep. 2013;5:878\u201385.","journal-title":"Cell Rep"},{"key":"8993_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.201","volume":"4","author":"DM Moujalled","year":"2013","unstructured":"Moujalled DM, Cook WD, Okamoto T, Murphy J, Lawlor KE, Vince JE, et al. TNF can activate RIPK3 and cause programmed necrosis in the absence of RIPK1. Cell Death Dis. 2013;4:e465.","journal-title":"Cell Death Dis"},{"key":"8993_CR56","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.cell.2009.05.037","volume":"137","author":"YS Cho","year":"2009","unstructured":"Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell. 2009;137:1112\u201323.","journal-title":"Cell"},{"key":"8993_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf6290","volume":"7","author":"Y Yang","year":"2021","unstructured":"Yang Y, Wu M, Cao D, Yang C, Jin J, Wu L, et al. ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation. Sci Adv. 2021;7:eabf6290.","journal-title":"Sci Adv"},{"key":"8993_CR58","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-022-04753-7","volume":"606","author":"T Zhang","year":"2022","unstructured":"Zhang T, Yin C, Fedorov A, Qiao L, Bao H, Beknazarov N, et al. ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis. Nature. 2022;606:594\u2013602.","journal-title":"Nature"},{"key":"8993_CR59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cytogfr.2024.03.005","volume":"77","author":"Q Song","year":"2024","unstructured":"Song Q, Fan Y, Zhang H, Wang N. Z-DNA binding protein 1 orchestrates innate immunity and inflammatory cell death. Cytokine Growth Factor Rev. 2024;77:15\u201329.","journal-title":"Cytokine Growth Factor Rev"},{"key":"8993_CR60","doi-asserted-by":"publisher","first-page":"19408","DOI":"10.1073\/pnas.2005010117","volume":"117","author":"MP Crawford","year":"2020","unstructured":"Crawford MP, Sinha S, Renavikar PS, Borcherding N, Karandikar NJ. CD4 T cell-intrinsic role for the T helper 17 signature cytokine IL-17: Effector resistance to immune suppression. Proc Natl Acad Sci USA. 2020;117:19408\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8993_CR61","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/eji.201747037","volume":"48","author":"AJ de Jong","year":"2018","unstructured":"de Jong AJ, Pollastro S, Kwekkeboom JC, Andersen SN, Dorjee AL, Bakker AM, et al. Functional and phenotypical analysis of IL-6-secreting CD4(+) T cells in human adipose tissue. Eur J Immunol. 2018;48:471\u201381.","journal-title":"Eur J Immunol"},{"key":"8993_CR62","doi-asserted-by":"crossref","unstructured":"Dicharry D, Malek AE. Unlocking the role of Treg cells immune response and infectious risk following CAR T-cell therapy in patients with cancer. Int J Mol Sci. 2025;26:1602.","DOI":"10.3390\/ijms26041602"},{"key":"8993_CR63","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.4049\/jimmunol.180.9.5771","volume":"180","author":"KN Couper","year":"2008","unstructured":"Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol. 2008;180:5771\u20137.","journal-title":"J Immunol"},{"key":"8993_CR64","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-140491","volume":"136","author":"T Siddiqi","year":"2020","unstructured":"Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason JE, et al. Updated follow-up of patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma treated with lisocabtagene maraleucel in the phase 1 monotherapy cohort of transcend CLL 004, including high-risk and ibrutinib-treated patients. Blood. 2020;136:40\u20131.","journal-title":"Blood"},{"key":"8993_CR65","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1097\/CAD.0b013e32832ced78","volume":"20","author":"DJ Chen","year":"2009","unstructured":"Chen DJ, Huerta S. Smac mimetics as new cancer therapeutics. Anticancer Drugs. 2009;20:646\u201358.","journal-title":"Anticancer Drugs"},{"key":"8993_CR66","doi-asserted-by":"crossref","unstructured":"Michie J, Kearney CJ, Hawkins ED, Silke J, Oliaro J. The immuno-modulatory effects of inhibitor of apoptosis protein antagonists in cancer immunotherapy. Cells. 2020;9:207.","DOI":"10.3390\/cells9010207"},{"key":"8993_CR67","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1158\/2326-6066.CIR-18-0428","volume":"7","author":"J Michie","year":"2019","unstructured":"Michie J, Beavis PA, Freeman AJ, Vervoort SJ, Ramsbottom KM, Narasimhan V, et al. Antagonism of IAPs enhances CAR T-cell Efficacy. Cancer Immunol Res. 2019;7:183\u201392.","journal-title":"Cancer Immunol Res"},{"key":"8993_CR68","doi-asserted-by":"publisher","first-page":"339ra70","DOI":"10.1126\/scitranslmed.aad2986","volume":"8","author":"S McComb","year":"2016","unstructured":"McComb S, Aguade-Gorgorio J, Harder L, Marovca B, Cario G, Eckert C, et al. Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL. Sci Transl Med. 2016;8:339ra70.","journal-title":"Sci Transl Med"},{"key":"8993_CR69","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1101\/gad.276725.115","volume":"30","author":"KL O\u2019Neill","year":"2016","unstructured":"O\u2019Neill KL, Huang K, Zhang J, Chen Y, Luo X. Inactivation of prosurvival Bcl-2 proteins activates Bax\/Bak through the outer mitochondrial membrane. Genes Dev. 2016;30:973\u201388.","journal-title":"Genes Dev"},{"key":"8993_CR70","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.celrep.2017.04.010","volume":"19","author":"S Horn","year":"2017","unstructured":"Horn S, Hughes MA, Schilling R, Sticht C, Tenev T, Ploesser M, et al. Caspase-10 negatively regulates caspase-8-mediated cell death, switching the response to CD95L in favor of NF-kappaB activation and cell survival. Cell Rep. 2017;19:785\u201397.","journal-title":"Cell Rep"},{"key":"8993_CR71","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.cell.2015.11.015","volume":"163","author":"T Hart","year":"2015","unstructured":"Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell. 2015;163:1515\u201326.","journal-title":"Cell"},{"key":"8993_CR72","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh1962","volume":"13","author":"A Katsarou","year":"2021","unstructured":"Katsarou A, Sjostrand M, Naik J, Mansilla-Soto J, Kefala D, Kladis G, et al. Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Sci Transl Med. 2021;13:eabh1962.","journal-title":"Sci Transl Med"},{"key":"8993_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgeb.2024.100446","volume":"22","author":"JJ van der Schans","year":"2024","unstructured":"van der Schans JJ, Katsarou A, Kladis G, Bar C, Ramirez MM, Themeli M, et al. A convenient viral transduction based method for advanced multi-engineering of primary human (CAR) T-cells. J Genet Eng Biotechnol. 2024;22:100446.","journal-title":"J Genet Eng Biotechnol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08993-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08993-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08993-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:03:05Z","timestamp":1789002185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08993-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8993"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08993-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"786"}}